Coherus BioSciences (CHRS) reported a Q4 non-GAAP net loss late Monday of $0.28 per diluted share, narrowing from a loss of $0.62 a year earlier.
Analysts surveyed by FactSet expected a loss of $0.19.
Total revenue for the quarter ended Dec. 31 was $54.1 million down from $91.5 million a year earlier.
Analysts polled by FactSet expected $44.1 million.
Chief Executive Officer Denny Lanfear said the company expects
cash position of about $250 million upon the completion of the UDENYCA divestiture and pay-off of its "significant" debt and royalty obligations.
"These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026," Lanfear said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。